Triglyceride-rich lipoprotein sphingolipids are altered in primary hypertension: A pilot case-control study
Open Access
- 28 March 2025
- journal article
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 19 (3) , 468-476
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Ceramides and other sphingolipids as drivers of cardiovascular diseaseNature Reviews Cardiology, 2021
- Association between increased plasma ceramides and chronic kidney disease in patients with and without ischemic heart diseaseDiabetes & Metabolism, 2021
- Association between specific plasma ceramides and high-sensitivity C-reactive protein levels in postmenopausal women with type 2 diabetesDiabetes & Metabolism, 2020
- Ceramides and risk of major adverse cardiovascular events: A meta-analysis of longitudinal studiesJournal of Clinical Lipidology, 2020
- An ANGPTL4–ceramide–protein kinase Cζ axis mediates chronic glucocorticoid exposure–induced hepatic steatosis and hypertriglyceridemia in miceJournal of Biological Chemistry, 2019
- Vascular transcriptome profiling identifies Sphingosine kinase 1 as a modulator of angiotensin II-induced vascular dysfunctionScientific Reports, 2017
- Pathophysiology of diabetic dyslipidaemia: where are we?Diabetologia, 2015
- Regulation of lipoprotein lipase by Angptl4Trends in Endocrinology & Metabolism, 2014
- Inhibitors of specific ceramide synthasesBiochimie, 2012
- Sample size of 12 per group rule of thumb for a pilot studyPharmaceutical Statistics, 2005